nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—HIF1A—esophageal cancer	0.406	0.76	CbGaD
Carvedilol—XDH—Carboplatin—esophageal cancer	0.0933	0.432	CbGbCtD
Carvedilol—PTGS1—esophageal cancer	0.0863	0.162	CbGaD
Carvedilol—XDH—Cisplatin—esophageal cancer	0.0797	0.369	CbGbCtD
Carvedilol—ABCB1—esophageal cancer	0.042	0.0785	CbGaD
Carvedilol—CYP2C9—Capecitabine—esophageal cancer	0.0186	0.086	CbGbCtD
Carvedilol—CYP2C9—Cisplatin—esophageal cancer	0.00936	0.0433	CbGbCtD
Carvedilol—ABCB1—Cisplatin—esophageal cancer	0.00908	0.0421	CbGbCtD
Carvedilol—ABCB1—Methotrexate—esophageal cancer	0.0059	0.0273	CbGbCtD
Carvedilol—NDUFC2—exocrine gland—esophageal cancer	0.00266	0.0416	CbGeAlD
Carvedilol—Methocarbamol—CA1—esophageal cancer	0.00233	0.915	CrCbGaD
Carvedilol—NPPB—smooth muscle tissue—esophageal cancer	0.00221	0.0345	CbGeAlD
Carvedilol—VCAM1—neck—esophageal cancer	0.00209	0.0327	CbGeAlD
Carvedilol—HIF1A—neck—esophageal cancer	0.00201	0.0315	CbGeAlD
Carvedilol—GJA1—neck—esophageal cancer	0.00195	0.0306	CbGeAlD
Carvedilol—NDUFC2—neck—esophageal cancer	0.0017	0.0266	CbGeAlD
Carvedilol—SELE—epithelium—esophageal cancer	0.00155	0.0242	CbGeAlD
Carvedilol—SELE—bronchus—esophageal cancer	0.00152	0.0238	CbGeAlD
Carvedilol—SELE—smooth muscle tissue—esophageal cancer	0.00149	0.0233	CbGeAlD
Carvedilol—VCAM1—epithelium—esophageal cancer	0.00142	0.0223	CbGeAlD
Carvedilol—VCAM1—bronchus—esophageal cancer	0.0014	0.0219	CbGeAlD
Carvedilol—VCAM1—smooth muscle tissue—esophageal cancer	0.00137	0.0215	CbGeAlD
Carvedilol—HIF1A—epithelium—esophageal cancer	0.00137	0.0214	CbGeAlD
Carvedilol—SELE—trachea—esophageal cancer	0.00137	0.0214	CbGeAlD
Carvedilol—HIF1A—bronchus—esophageal cancer	0.00135	0.0211	CbGeAlD
Carvedilol—GJA1—epithelium—esophageal cancer	0.00133	0.0208	CbGeAlD
Carvedilol—HIF1A—smooth muscle tissue—esophageal cancer	0.00132	0.0207	CbGeAlD
Carvedilol—GJA1—bronchus—esophageal cancer	0.00131	0.0205	CbGeAlD
Carvedilol—GJA1—smooth muscle tissue—esophageal cancer	0.00128	0.02	CbGeAlD
Carvedilol—VCAM1—trachea—esophageal cancer	0.00126	0.0197	CbGeAlD
Carvedilol—HIF1A—trachea—esophageal cancer	0.00121	0.019	CbGeAlD
Carvedilol—SELE—digestive system—esophageal cancer	0.00118	0.0184	CbGeAlD
Carvedilol—GJA1—trachea—esophageal cancer	0.00118	0.0184	CbGeAlD
Carvedilol—NDUFC2—epithelium—esophageal cancer	0.00116	0.0181	CbGeAlD
Carvedilol—NDUFC2—bronchus—esophageal cancer	0.00114	0.0178	CbGeAlD
Carvedilol—VCAM1—digestive system—esophageal cancer	0.00108	0.0169	CbGeAlD
Carvedilol—HIF1A—digestive system—esophageal cancer	0.00104	0.0163	CbGeAlD
Carvedilol—VEGFA—bronchus—esophageal cancer	0.00103	0.0162	CbGeAlD
Carvedilol—NDUFC2—trachea—esophageal cancer	0.00102	0.016	CbGeAlD
Carvedilol—VEGFA—smooth muscle tissue—esophageal cancer	0.00101	0.0158	CbGeAlD
Carvedilol—GJA1—digestive system—esophageal cancer	0.00101	0.0158	CbGeAlD
Carvedilol—SELE—lung—esophageal cancer	0.000984	0.0154	CbGeAlD
Carvedilol—VEGFA—trachea—esophageal cancer	0.000928	0.0145	CbGeAlD
Carvedilol—VCAM1—lung—esophageal cancer	0.000905	0.0142	CbGeAlD
Carvedilol—NDUFC2—digestive system—esophageal cancer	0.00088	0.0138	CbGeAlD
Carvedilol—HIF1A—lung—esophageal cancer	0.00087	0.0136	CbGeAlD
Carvedilol—GJA1—lung—esophageal cancer	0.000844	0.0132	CbGeAlD
Carvedilol—NDUFC2—lung—esophageal cancer	0.000735	0.0115	CbGeAlD
Carvedilol—XDH—digestive system—esophageal cancer	0.000711	0.0111	CbGeAlD
Carvedilol—ADRA1D—epithelium—esophageal cancer	0.000686	0.0107	CbGeAlD
Carvedilol—SELE—lymph node—esophageal cancer	0.000673	0.0105	CbGeAlD
Carvedilol—VEGFA—lung—esophageal cancer	0.000667	0.0104	CbGeAlD
Carvedilol—VCAM1—lymph node—esophageal cancer	0.000619	0.00968	CbGeAlD
Carvedilol—HIF1A—lymph node—esophageal cancer	0.000595	0.00931	CbGeAlD
Carvedilol—GJA1—lymph node—esophageal cancer	0.000578	0.00903	CbGeAlD
Carvedilol—NDUFC2—lymph node—esophageal cancer	0.000503	0.00786	CbGeAlD
Carvedilol—ADRB1—bronchus—esophageal cancer	0.00049	0.00767	CbGeAlD
Carvedilol—VEGFA—lymph node—esophageal cancer	0.000456	0.00713	CbGeAlD
Carvedilol—ADRA1A—epithelium—esophageal cancer	0.000394	0.00616	CbGeAlD
Carvedilol—ADRA2C—bronchus—esophageal cancer	0.00037	0.00578	CbGeAlD
Carvedilol—ADRA2C—trachea—esophageal cancer	0.000332	0.00519	CbGeAlD
Carvedilol—CYP1A1—epithelium—esophageal cancer	0.000321	0.00502	CbGeAlD
Carvedilol—ADRB1—lung—esophageal cancer	0.000316	0.00495	CbGeAlD
Carvedilol—CYP1A1—bronchus—esophageal cancer	0.000316	0.00495	CbGeAlD
Carvedilol—ADRA2A—bronchus—esophageal cancer	0.000295	0.00461	CbGeAlD
Carvedilol—CYP1A1—trachea—esophageal cancer	0.000284	0.00444	CbGeAlD
Carvedilol—PTGS1—epithelium—esophageal cancer	0.000282	0.00441	CbGeAlD
Carvedilol—PTGS1—smooth muscle tissue—esophageal cancer	0.000272	0.00425	CbGeAlD
Carvedilol—ADRA2A—trachea—esophageal cancer	0.000265	0.00414	CbGeAlD
Carvedilol—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.000252	0.00395	CcSEcCtD
Carvedilol—Sweating increased—Cisplatin—esophageal cancer	0.000251	0.00392	CcSEcCtD
Carvedilol—PTGS1—trachea—esophageal cancer	0.00025	0.0039	CbGeAlD
Carvedilol—Swelling—Capecitabine—esophageal cancer	0.000249	0.00389	CcSEcCtD
Carvedilol—CYP1A2—digestive system—esophageal cancer	0.000248	0.00387	CbGeAlD
Carvedilol—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.000248	0.00387	CcSEcCtD
Carvedilol—Vascular purpura—Capecitabine—esophageal cancer	0.000245	0.00384	CcSEcCtD
Carvedilol—Pancytopenia—Cisplatin—esophageal cancer	0.000244	0.00383	CcSEcCtD
Carvedilol—CYP1A1—digestive system—esophageal cancer	0.000244	0.00382	CbGeAlD
Carvedilol—Hyperuricaemia—Methotrexate—esophageal cancer	0.000243	0.0038	CcSEcCtD
Carvedilol—ADRA2C—lung—esophageal cancer	0.000238	0.00373	CbGeAlD
Carvedilol—Renal failure acute—Capecitabine—esophageal cancer	0.000238	0.00372	CcSEcCtD
Carvedilol—Libido decreased—Capecitabine—esophageal cancer	0.000237	0.0037	CcSEcCtD
Carvedilol—CYP2C9—digestive system—esophageal cancer	0.000235	0.00368	CbGeAlD
Carvedilol—Amnesia—Capecitabine—esophageal cancer	0.000234	0.00366	CcSEcCtD
Carvedilol—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.000233	0.00364	CcSEcCtD
Carvedilol—Atrial fibrillation—Capecitabine—esophageal cancer	0.000232	0.00363	CcSEcCtD
Carvedilol—Renal impairment—Capecitabine—esophageal cancer	0.000231	0.00361	CcSEcCtD
Carvedilol—Blood uric acid increased—Methotrexate—esophageal cancer	0.000229	0.00359	CcSEcCtD
Carvedilol—Purpura—Capecitabine—esophageal cancer	0.000228	0.00356	CcSEcCtD
Carvedilol—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000226	0.00354	CcSEcCtD
Carvedilol—Arthritis—Capecitabine—esophageal cancer	0.000226	0.00354	CcSEcCtD
Carvedilol—Renal failure—Cisplatin—esophageal cancer	0.000226	0.00353	CcSEcCtD
Carvedilol—Myocardial infarction—Cisplatin—esophageal cancer	0.000225	0.00352	CcSEcCtD
Carvedilol—Cardiac failure—Capecitabine—esophageal cancer	0.000225	0.00352	CcSEcCtD
Carvedilol—Cerebrovascular accident—Capecitabine—esophageal cancer	0.000224	0.00351	CcSEcCtD
Carvedilol—CYP2E1—digestive system—esophageal cancer	0.000223	0.00349	CbGeAlD
Carvedilol—Hyponatraemia—Capecitabine—esophageal cancer	0.00022	0.00345	CcSEcCtD
Carvedilol—Melaena—Methotrexate—esophageal cancer	0.00022	0.00344	CcSEcCtD
Carvedilol—Pain in extremity—Capecitabine—esophageal cancer	0.000219	0.00344	CcSEcCtD
Carvedilol—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.000219	0.00344	CcSEcCtD
Carvedilol—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.000218	0.00341	CcSEcCtD
Carvedilol—Migraine—Capecitabine—esophageal cancer	0.000216	0.00338	CcSEcCtD
Carvedilol—PTGS1—digestive system—esophageal cancer	0.000215	0.00336	CbGeAlD
Carvedilol—Aplastic anaemia—Methotrexate—esophageal cancer	0.000211	0.00331	CcSEcCtD
Carvedilol—Bradycardia—Cisplatin—esophageal cancer	0.00021	0.00328	CcSEcCtD
Carvedilol—Cardiac arrest—Capecitabine—esophageal cancer	0.000209	0.00327	CcSEcCtD
Carvedilol—Mood swings—Capecitabine—esophageal cancer	0.000208	0.00325	CcSEcCtD
Carvedilol—CYP1A2—lung—esophageal cancer	0.000207	0.00324	CbGeAlD
Carvedilol—Blood creatinine increased—Capecitabine—esophageal cancer	0.000206	0.00322	CcSEcCtD
Carvedilol—Dehydration—Capecitabine—esophageal cancer	0.000204	0.0032	CcSEcCtD
Carvedilol—CYP1A1—lung—esophageal cancer	0.000204	0.00319	CbGeAlD
Carvedilol—Urinary tract disorder—Cisplatin—esophageal cancer	0.000203	0.00318	CcSEcCtD
Carvedilol—Urethral disorder—Cisplatin—esophageal cancer	0.000202	0.00316	CcSEcCtD
Carvedilol—Orthostatic hypotension—Capecitabine—esophageal cancer	0.0002	0.00314	CcSEcCtD
Carvedilol—Pulmonary oedema—Methotrexate—esophageal cancer	0.0002	0.00314	CcSEcCtD
Carvedilol—Hypokalaemia—Capecitabine—esophageal cancer	0.0002	0.00313	CcSEcCtD
Carvedilol—Visual impairment—Cisplatin—esophageal cancer	0.000199	0.00311	CcSEcCtD
Carvedilol—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000198	0.00309	CcSEcCtD
Carvedilol—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000198	0.00309	CcSEcCtD
Carvedilol—Nasopharyngitis—Capecitabine—esophageal cancer	0.000196	0.00307	CcSEcCtD
Carvedilol—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000194	0.00303	CcSEcCtD
Carvedilol—Tinnitus—Cisplatin—esophageal cancer	0.000192	0.00301	CcSEcCtD
Carvedilol—ADRA2A—lung—esophageal cancer	0.00019	0.00298	CbGeAlD
Carvedilol—Influenza—Capecitabine—esophageal cancer	0.00019	0.00297	CcSEcCtD
Carvedilol—Diabetes mellitus—Methotrexate—esophageal cancer	0.000188	0.00294	CcSEcCtD
Carvedilol—Bronchospasm—Capecitabine—esophageal cancer	0.000187	0.00292	CcSEcCtD
Carvedilol—CYP2E1—lung—esophageal cancer	0.000186	0.00291	CbGeAlD
Carvedilol—Immune system disorder—Cisplatin—esophageal cancer	0.000186	0.00291	CcSEcCtD
Carvedilol—Mediastinal disorder—Cisplatin—esophageal cancer	0.000186	0.00291	CcSEcCtD
Carvedilol—Angina pectoris—Capecitabine—esophageal cancer	0.000185	0.00289	CcSEcCtD
Carvedilol—Sweating increased—Capecitabine—esophageal cancer	0.000185	0.00289	CcSEcCtD
Carvedilol—Bronchitis—Capecitabine—esophageal cancer	0.000182	0.00286	CcSEcCtD
Carvedilol—Alopecia—Cisplatin—esophageal cancer	0.000182	0.00285	CcSEcCtD
Carvedilol—Pancytopenia—Capecitabine—esophageal cancer	0.00018	0.00282	CcSEcCtD
Carvedilol—Malnutrition—Cisplatin—esophageal cancer	0.000179	0.00281	CcSEcCtD
Carvedilol—CYP3A4—digestive system—esophageal cancer	0.000179	0.0028	CbGeAlD
Carvedilol—PTGS1—lung—esophageal cancer	0.000179	0.0028	CbGeAlD
Carvedilol—Renal failure acute—Methotrexate—esophageal cancer	0.000177	0.00277	CcSEcCtD
Carvedilol—Flatulence—Cisplatin—esophageal cancer	0.000177	0.00277	CcSEcCtD
Carvedilol—CYP2D6—digestive system—esophageal cancer	0.000176	0.00276	CbGeAlD
Carvedilol—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000176	0.00276	CcSEcCtD
Carvedilol—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000173	0.00271	CcSEcCtD
Carvedilol—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000173	0.00271	CcSEcCtD
Carvedilol—Weight increased—Capecitabine—esophageal cancer	0.000173	0.0027	CcSEcCtD
Carvedilol—Muscle spasms—Cisplatin—esophageal cancer	0.000172	0.0027	CcSEcCtD
Carvedilol—Weight decreased—Capecitabine—esophageal cancer	0.000172	0.00269	CcSEcCtD
Carvedilol—Hyperglycaemia—Capecitabine—esophageal cancer	0.000171	0.00268	CcSEcCtD
Carvedilol—Pneumonia—Capecitabine—esophageal cancer	0.00017	0.00266	CcSEcCtD
Carvedilol—Vision blurred—Cisplatin—esophageal cancer	0.000169	0.00265	CcSEcCtD
Carvedilol—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000169	0.00264	CcSEcCtD
Carvedilol—Depression—Capecitabine—esophageal cancer	0.000169	0.00264	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000168	0.00262	CcSEcCtD
Carvedilol—ABCB1—epithelium—esophageal cancer	0.000167	0.00261	CbGeAlD
Carvedilol—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000167	0.00261	CcSEcCtD
Carvedilol—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000167	0.00261	CcSEcCtD
Carvedilol—Ill-defined disorder—Cisplatin—esophageal cancer	0.000166	0.0026	CcSEcCtD
Carvedilol—Renal failure—Capecitabine—esophageal cancer	0.000166	0.0026	CcSEcCtD
Carvedilol—Myocardial infarction—Capecitabine—esophageal cancer	0.000166	0.0026	CcSEcCtD
Carvedilol—Anaemia—Cisplatin—esophageal cancer	0.000166	0.00259	CcSEcCtD
Carvedilol—KCNH2—lymph node—esophageal cancer	0.000165	0.00259	CbGeAlD
Carvedilol—Urinary tract infection—Capecitabine—esophageal cancer	0.000164	0.00257	CcSEcCtD
Carvedilol—ADRA2C—lymph node—esophageal cancer	0.000163	0.00255	CbGeAlD
Carvedilol—Malaise—Cisplatin—esophageal cancer	0.000162	0.00253	CcSEcCtD
Carvedilol—Haematuria—Capecitabine—esophageal cancer	0.000161	0.00252	CcSEcCtD
Carvedilol—Leukopenia—Cisplatin—esophageal cancer	0.000161	0.00251	CcSEcCtD
Carvedilol—Convulsion—Cisplatin—esophageal cancer	0.000155	0.00243	CcSEcCtD
Carvedilol—Mood swings—Methotrexate—esophageal cancer	0.000155	0.00242	CcSEcCtD
Carvedilol—Bradycardia—Capecitabine—esophageal cancer	0.000155	0.00242	CcSEcCtD
Carvedilol—Myalgia—Cisplatin—esophageal cancer	0.000153	0.00239	CcSEcCtD
Carvedilol—Haemoglobin—Capecitabine—esophageal cancer	0.000153	0.00239	CcSEcCtD
Carvedilol—Rhinitis—Capecitabine—esophageal cancer	0.000152	0.00238	CcSEcCtD
Carvedilol—Haemorrhage—Capecitabine—esophageal cancer	0.000152	0.00238	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000152	0.00237	CcSEcCtD
Carvedilol—Hypoaesthesia—Capecitabine—esophageal cancer	0.000151	0.00236	CcSEcCtD
Carvedilol—Discomfort—Cisplatin—esophageal cancer	0.000151	0.00236	CcSEcCtD
Carvedilol—Pharyngitis—Capecitabine—esophageal cancer	0.000151	0.00236	CcSEcCtD
Carvedilol—Urinary tract disorder—Capecitabine—esophageal cancer	0.00015	0.00235	CcSEcCtD
Carvedilol—Oedema peripheral—Capecitabine—esophageal cancer	0.00015	0.00234	CcSEcCtD
Carvedilol—Urethral disorder—Capecitabine—esophageal cancer	0.000149	0.00233	CcSEcCtD
Carvedilol—ABCB1—trachea—esophageal cancer	0.000148	0.00231	CbGeAlD
Carvedilol—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000147	0.0023	CcSEcCtD
Carvedilol—Oedema—Cisplatin—esophageal cancer	0.000146	0.00229	CcSEcCtD
Carvedilol—Anaphylactic shock—Cisplatin—esophageal cancer	0.000146	0.00229	CcSEcCtD
Carvedilol—Visual impairment—Capecitabine—esophageal cancer	0.000146	0.00229	CcSEcCtD
Carvedilol—Infection—Cisplatin—esophageal cancer	0.000145	0.00228	CcSEcCtD
Carvedilol—Erythema multiforme—Capecitabine—esophageal cancer	0.000144	0.00225	CcSEcCtD
Carvedilol—Thrombocytopenia—Cisplatin—esophageal cancer	0.000143	0.00224	CcSEcCtD
Carvedilol—Tachycardia—Cisplatin—esophageal cancer	0.000143	0.00224	CcSEcCtD
Carvedilol—Skin disorder—Cisplatin—esophageal cancer	0.000142	0.00223	CcSEcCtD
Carvedilol—Tinnitus—Capecitabine—esophageal cancer	0.000142	0.00222	CcSEcCtD
Carvedilol—Hyperhidrosis—Cisplatin—esophageal cancer	0.000141	0.00221	CcSEcCtD
Carvedilol—CYP1A1—lymph node—esophageal cancer	0.00014	0.00218	CbGeAlD
Carvedilol—Anorexia—Cisplatin—esophageal cancer	0.000139	0.00218	CcSEcCtD
Carvedilol—Angiopathy—Capecitabine—esophageal cancer	0.000138	0.00216	CcSEcCtD
Carvedilol—Immune system disorder—Capecitabine—esophageal cancer	0.000137	0.00215	CcSEcCtD
Carvedilol—Mediastinal disorder—Capecitabine—esophageal cancer	0.000137	0.00214	CcSEcCtD
Carvedilol—Hypotension—Cisplatin—esophageal cancer	0.000137	0.00214	CcSEcCtD
Carvedilol—Alopecia—Capecitabine—esophageal cancer	0.000134	0.0021	CcSEcCtD
Carvedilol—Pancytopenia—Methotrexate—esophageal cancer	0.000134	0.0021	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000133	0.00209	CcSEcCtD
Carvedilol—Malnutrition—Capecitabine—esophageal cancer	0.000132	0.00207	CcSEcCtD
Carvedilol—Paraesthesia—Cisplatin—esophageal cancer	0.000131	0.00206	CcSEcCtD
Carvedilol—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000131	0.00205	CcSEcCtD
Carvedilol—Dyspnoea—Cisplatin—esophageal cancer	0.00013	0.00204	CcSEcCtD
Carvedilol—Flatulence—Capecitabine—esophageal cancer	0.00013	0.00204	CcSEcCtD
Carvedilol—ADRA2A—lymph node—esophageal cancer	0.00013	0.00204	CbGeAlD
Carvedilol—Erectile dysfunction—Methotrexate—esophageal cancer	0.00013	0.00204	CcSEcCtD
Carvedilol—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000129	0.00202	CcSEcCtD
Carvedilol—Propafenone—ABCB1—esophageal cancer	0.000129	0.0505	CrCbGaD
Carvedilol—Back pain—Capecitabine—esophageal cancer	0.000128	0.002	CcSEcCtD
Carvedilol—Decreased appetite—Cisplatin—esophageal cancer	0.000127	0.00199	CcSEcCtD
Carvedilol—Muscle spasms—Capecitabine—esophageal cancer	0.000127	0.00199	CcSEcCtD
Carvedilol—ABCB1—digestive system—esophageal cancer	0.000127	0.00199	CbGeAlD
Carvedilol—Pneumonia—Methotrexate—esophageal cancer	0.000127	0.00198	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000126	0.00198	CcSEcCtD
Carvedilol—Depression—Methotrexate—esophageal cancer	0.000126	0.00197	CcSEcCtD
Carvedilol—Pain—Cisplatin—esophageal cancer	0.000125	0.00196	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000125	0.00195	CcSEcCtD
Carvedilol—Vision blurred—Capecitabine—esophageal cancer	0.000125	0.00195	CcSEcCtD
Carvedilol—Renal failure—Methotrexate—esophageal cancer	0.000124	0.00194	CcSEcCtD
Carvedilol—Ill-defined disorder—Capecitabine—esophageal cancer	0.000123	0.00192	CcSEcCtD
Carvedilol—PTGS1—lymph node—esophageal cancer	0.000123	0.00192	CbGeAlD
Carvedilol—Anaemia—Capecitabine—esophageal cancer	0.000122	0.00191	CcSEcCtD
Carvedilol—Feeling abnormal—Cisplatin—esophageal cancer	0.000121	0.00189	CcSEcCtD
Carvedilol—Haematuria—Methotrexate—esophageal cancer	0.00012	0.00188	CcSEcCtD
Carvedilol—Malaise—Capecitabine—esophageal cancer	0.000119	0.00187	CcSEcCtD
Carvedilol—Vertigo—Capecitabine—esophageal cancer	0.000119	0.00186	CcSEcCtD
Carvedilol—Syncope—Capecitabine—esophageal cancer	0.000119	0.00186	CcSEcCtD
Carvedilol—Leukopenia—Capecitabine—esophageal cancer	0.000118	0.00185	CcSEcCtD
Carvedilol—Palpitations—Capecitabine—esophageal cancer	0.000117	0.00183	CcSEcCtD
Carvedilol—Loss of consciousness—Capecitabine—esophageal cancer	0.000116	0.00182	CcSEcCtD
Carvedilol—Body temperature increased—Cisplatin—esophageal cancer	0.000116	0.00181	CcSEcCtD
Carvedilol—Cough—Capecitabine—esophageal cancer	0.000115	0.00181	CcSEcCtD
Carvedilol—Hypertension—Capecitabine—esophageal cancer	0.000114	0.00179	CcSEcCtD
Carvedilol—Haemoglobin—Methotrexate—esophageal cancer	0.000114	0.00178	CcSEcCtD
Carvedilol—Haemorrhage—Methotrexate—esophageal cancer	0.000113	0.00177	CcSEcCtD
Carvedilol—Arthralgia—Capecitabine—esophageal cancer	0.000113	0.00176	CcSEcCtD
Carvedilol—Myalgia—Capecitabine—esophageal cancer	0.000113	0.00176	CcSEcCtD
Carvedilol—Chest pain—Capecitabine—esophageal cancer	0.000113	0.00176	CcSEcCtD
Carvedilol—Pharyngitis—Methotrexate—esophageal cancer	0.000112	0.00176	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000112	0.00175	CcSEcCtD
Carvedilol—Urinary tract disorder—Methotrexate—esophageal cancer	0.000112	0.00175	CcSEcCtD
Carvedilol—Discomfort—Capecitabine—esophageal cancer	0.000111	0.00174	CcSEcCtD
Carvedilol—Urethral disorder—Methotrexate—esophageal cancer	0.000111	0.00173	CcSEcCtD
Carvedilol—Dry mouth—Capecitabine—esophageal cancer	0.00011	0.00172	CcSEcCtD
Carvedilol—Visual impairment—Methotrexate—esophageal cancer	0.000109	0.00171	CcSEcCtD
Carvedilol—Confusional state—Capecitabine—esophageal cancer	0.000109	0.0017	CcSEcCtD
Carvedilol—Oedema—Capecitabine—esophageal cancer	0.000108	0.00169	CcSEcCtD
Carvedilol—Hypersensitivity—Cisplatin—esophageal cancer	0.000108	0.00169	CcSEcCtD
Carvedilol—Infection—Capecitabine—esophageal cancer	0.000107	0.00168	CcSEcCtD
Carvedilol—Erythema multiforme—Methotrexate—esophageal cancer	0.000107	0.00167	CcSEcCtD
Carvedilol—Shock—Capecitabine—esophageal cancer	0.000106	0.00166	CcSEcCtD
Carvedilol—ABCB1—lung—esophageal cancer	0.000106	0.00166	CbGeAlD
Carvedilol—Thrombocytopenia—Capecitabine—esophageal cancer	0.000106	0.00165	CcSEcCtD
Carvedilol—Tinnitus—Methotrexate—esophageal cancer	0.000105	0.00165	CcSEcCtD
Carvedilol—Tachycardia—Capecitabine—esophageal cancer	0.000105	0.00165	CcSEcCtD
Carvedilol—Asthenia—Cisplatin—esophageal cancer	0.000105	0.00164	CcSEcCtD
Carvedilol—Skin disorder—Capecitabine—esophageal cancer	0.000105	0.00164	CcSEcCtD
Carvedilol—Hyperhidrosis—Capecitabine—esophageal cancer	0.000104	0.00163	CcSEcCtD
Carvedilol—Anorexia—Capecitabine—esophageal cancer	0.000103	0.00161	CcSEcCtD
Carvedilol—Angiopathy—Methotrexate—esophageal cancer	0.000103	0.00161	CcSEcCtD
Carvedilol—Immune system disorder—Methotrexate—esophageal cancer	0.000102	0.0016	CcSEcCtD
Carvedilol—Mediastinal disorder—Methotrexate—esophageal cancer	0.000102	0.00159	CcSEcCtD
Carvedilol—Hypotension—Capecitabine—esophageal cancer	0.000101	0.00158	CcSEcCtD
Carvedilol—Diarrhoea—Cisplatin—esophageal cancer	0.0001	0.00157	CcSEcCtD
Carvedilol—Alopecia—Methotrexate—esophageal cancer	9.99e-05	0.00156	CcSEcCtD
Carvedilol—Malnutrition—Methotrexate—esophageal cancer	9.84e-05	0.00154	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Capecitabine—esophageal cancer	9.83e-05	0.00154	CcSEcCtD
Carvedilol—Insomnia—Capecitabine—esophageal cancer	9.76e-05	0.00153	CcSEcCtD
Carvedilol—Paraesthesia—Capecitabine—esophageal cancer	9.69e-05	0.00152	CcSEcCtD
Carvedilol—Dyspnoea—Capecitabine—esophageal cancer	9.62e-05	0.00151	CcSEcCtD
Carvedilol—Back pain—Methotrexate—esophageal cancer	9.52e-05	0.00149	CcSEcCtD
Carvedilol—Dyspepsia—Capecitabine—esophageal cancer	9.5e-05	0.00149	CcSEcCtD
Carvedilol—Decreased appetite—Capecitabine—esophageal cancer	9.38e-05	0.00147	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Capecitabine—esophageal cancer	9.31e-05	0.00146	CcSEcCtD
Carvedilol—Vomiting—Cisplatin—esophageal cancer	9.3e-05	0.00146	CcSEcCtD
Carvedilol—Fatigue—Capecitabine—esophageal cancer	9.3e-05	0.00146	CcSEcCtD
Carvedilol—Vision blurred—Methotrexate—esophageal cancer	9.27e-05	0.00145	CcSEcCtD
Carvedilol—Rash—Cisplatin—esophageal cancer	9.23e-05	0.00144	CcSEcCtD
Carvedilol—Pain—Capecitabine—esophageal cancer	9.22e-05	0.00144	CcSEcCtD
Carvedilol—Constipation—Capecitabine—esophageal cancer	9.22e-05	0.00144	CcSEcCtD
Carvedilol—Dermatitis—Cisplatin—esophageal cancer	9.22e-05	0.00144	CcSEcCtD
Carvedilol—Ill-defined disorder—Methotrexate—esophageal cancer	9.13e-05	0.00143	CcSEcCtD
Carvedilol—Anaemia—Methotrexate—esophageal cancer	9.09e-05	0.00142	CcSEcCtD
Carvedilol—Feeling abnormal—Capecitabine—esophageal cancer	8.89e-05	0.00139	CcSEcCtD
Carvedilol—Malaise—Methotrexate—esophageal cancer	8.87e-05	0.00139	CcSEcCtD
Carvedilol—Vertigo—Methotrexate—esophageal cancer	8.84e-05	0.00138	CcSEcCtD
Carvedilol—Gastrointestinal pain—Capecitabine—esophageal cancer	8.82e-05	0.00138	CcSEcCtD
Carvedilol—Leukopenia—Methotrexate—esophageal cancer	8.81e-05	0.00138	CcSEcCtD
Carvedilol—Propranolol—ABCB1—esophageal cancer	8.81e-05	0.0346	CrCbGaD
Carvedilol—Nausea—Cisplatin—esophageal cancer	8.69e-05	0.00136	CcSEcCtD
Carvedilol—Cough—Methotrexate—esophageal cancer	8.59e-05	0.00134	CcSEcCtD
Carvedilol—Urticaria—Capecitabine—esophageal cancer	8.57e-05	0.00134	CcSEcCtD
Carvedilol—Abdominal pain—Capecitabine—esophageal cancer	8.53e-05	0.00133	CcSEcCtD
Carvedilol—Body temperature increased—Capecitabine—esophageal cancer	8.53e-05	0.00133	CcSEcCtD
Carvedilol—Convulsion—Methotrexate—esophageal cancer	8.53e-05	0.00133	CcSEcCtD
Carvedilol—Chest pain—Methotrexate—esophageal cancer	8.38e-05	0.00131	CcSEcCtD
Carvedilol—Myalgia—Methotrexate—esophageal cancer	8.38e-05	0.00131	CcSEcCtD
Carvedilol—Arthralgia—Methotrexate—esophageal cancer	8.38e-05	0.00131	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	8.32e-05	0.0013	CcSEcCtD
Carvedilol—Discomfort—Methotrexate—esophageal cancer	8.28e-05	0.0013	CcSEcCtD
Carvedilol—Confusional state—Methotrexate—esophageal cancer	8.1e-05	0.00127	CcSEcCtD
Carvedilol—Anaphylactic shock—Methotrexate—esophageal cancer	8.03e-05	0.00126	CcSEcCtD
Carvedilol—Infection—Methotrexate—esophageal cancer	7.98e-05	0.00125	CcSEcCtD
Carvedilol—Hypersensitivity—Capecitabine—esophageal cancer	7.95e-05	0.00124	CcSEcCtD
Carvedilol—Thrombocytopenia—Methotrexate—esophageal cancer	7.86e-05	0.00123	CcSEcCtD
Carvedilol—Skin disorder—Methotrexate—esophageal cancer	7.8e-05	0.00122	CcSEcCtD
Carvedilol—Hyperhidrosis—Methotrexate—esophageal cancer	7.76e-05	0.00122	CcSEcCtD
Carvedilol—Asthenia—Capecitabine—esophageal cancer	7.74e-05	0.00121	CcSEcCtD
Carvedilol—Anorexia—Methotrexate—esophageal cancer	7.65e-05	0.0012	CcSEcCtD
Carvedilol—Pruritus—Capecitabine—esophageal cancer	7.63e-05	0.00119	CcSEcCtD
Carvedilol—Hypotension—Methotrexate—esophageal cancer	7.5e-05	0.00117	CcSEcCtD
Carvedilol—Diarrhoea—Capecitabine—esophageal cancer	7.38e-05	0.00116	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Methotrexate—esophageal cancer	7.32e-05	0.00115	CcSEcCtD
Carvedilol—Insomnia—Methotrexate—esophageal cancer	7.26e-05	0.00114	CcSEcCtD
Carvedilol—ABCB1—lymph node—esophageal cancer	7.25e-05	0.00113	CbGeAlD
Carvedilol—Paraesthesia—Methotrexate—esophageal cancer	7.21e-05	0.00113	CcSEcCtD
Carvedilol—Dyspnoea—Methotrexate—esophageal cancer	7.16e-05	0.00112	CcSEcCtD
Carvedilol—Somnolence—Methotrexate—esophageal cancer	7.14e-05	0.00112	CcSEcCtD
Carvedilol—Dizziness—Capecitabine—esophageal cancer	7.13e-05	0.00112	CcSEcCtD
Carvedilol—Dyspepsia—Methotrexate—esophageal cancer	7.07e-05	0.00111	CcSEcCtD
Carvedilol—Decreased appetite—Methotrexate—esophageal cancer	6.98e-05	0.00109	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Methotrexate—esophageal cancer	6.93e-05	0.00109	CcSEcCtD
Carvedilol—Fatigue—Methotrexate—esophageal cancer	6.92e-05	0.00108	CcSEcCtD
Carvedilol—Pain—Methotrexate—esophageal cancer	6.87e-05	0.00107	CcSEcCtD
Carvedilol—Vomiting—Capecitabine—esophageal cancer	6.86e-05	0.00107	CcSEcCtD
Carvedilol—Rash—Capecitabine—esophageal cancer	6.8e-05	0.00106	CcSEcCtD
Carvedilol—Dermatitis—Capecitabine—esophageal cancer	6.8e-05	0.00106	CcSEcCtD
Carvedilol—Headache—Capecitabine—esophageal cancer	6.76e-05	0.00106	CcSEcCtD
Carvedilol—Feeling abnormal—Methotrexate—esophageal cancer	6.62e-05	0.00104	CcSEcCtD
Carvedilol—Gastrointestinal pain—Methotrexate—esophageal cancer	6.57e-05	0.00103	CcSEcCtD
Carvedilol—Nausea—Capecitabine—esophageal cancer	6.41e-05	0.001	CcSEcCtD
Carvedilol—Urticaria—Methotrexate—esophageal cancer	6.38e-05	0.000999	CcSEcCtD
Carvedilol—Body temperature increased—Methotrexate—esophageal cancer	6.35e-05	0.000994	CcSEcCtD
Carvedilol—Abdominal pain—Methotrexate—esophageal cancer	6.35e-05	0.000994	CcSEcCtD
Carvedilol—Hypersensitivity—Methotrexate—esophageal cancer	5.92e-05	0.000926	CcSEcCtD
Carvedilol—Asthenia—Methotrexate—esophageal cancer	5.76e-05	0.000902	CcSEcCtD
Carvedilol—Pruritus—Methotrexate—esophageal cancer	5.68e-05	0.000889	CcSEcCtD
Carvedilol—Diarrhoea—Methotrexate—esophageal cancer	5.49e-05	0.00086	CcSEcCtD
Carvedilol—Dizziness—Methotrexate—esophageal cancer	5.31e-05	0.000831	CcSEcCtD
Carvedilol—Vomiting—Methotrexate—esophageal cancer	5.11e-05	0.000799	CcSEcCtD
Carvedilol—Rash—Methotrexate—esophageal cancer	5.06e-05	0.000793	CcSEcCtD
Carvedilol—Dermatitis—Methotrexate—esophageal cancer	5.06e-05	0.000792	CcSEcCtD
Carvedilol—Headache—Methotrexate—esophageal cancer	5.03e-05	0.000787	CcSEcCtD
Carvedilol—Nausea—Methotrexate—esophageal cancer	4.77e-05	0.000747	CcSEcCtD
Carvedilol—CYP2D6—Metabolism—PSME2—esophageal cancer	3.24e-06	2.72e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PSME1—esophageal cancer	3.24e-06	2.72e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—HIF1A—esophageal cancer	3.21e-06	2.69e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PSME2—esophageal cancer	3.21e-06	2.69e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PSME1—esophageal cancer	3.21e-06	2.69e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—HMOX1—esophageal cancer	3.19e-06	2.67e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—HIF1A—esophageal cancer	3.19e-06	2.67e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CYP26A1—esophageal cancer	3.18e-06	2.67e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—SMAD4—esophageal cancer	3.18e-06	2.66e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—NOTCH1—esophageal cancer	3.18e-06	2.66e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—CDKN1A—esophageal cancer	3.17e-06	2.65e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—CDKN1A—esophageal cancer	3.16e-06	2.65e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—HIF1A—esophageal cancer	3.14e-06	2.64e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.13e-06	2.62e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ALDH2—esophageal cancer	3.12e-06	2.62e-05	CbGpPWpGaD
Carvedilol—XDH—Metabolism—PIK3CA—esophageal cancer	3.12e-06	2.62e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TGFBR2—esophageal cancer	3.12e-06	2.62e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ALOX15—esophageal cancer	3.1e-06	2.6e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KDR—esophageal cancer	3.07e-06	2.58e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—ABCB1—esophageal cancer	3.06e-06	2.56e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—KDR—esophageal cancer	3.05e-06	2.55e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—EP300—esophageal cancer	3.01e-06	2.53e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KDR—esophageal cancer	3.01e-06	2.52e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—EP300—esophageal cancer	3.01e-06	2.52e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—HIF1A—esophageal cancer	2.98e-06	2.49e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—GSTT1—esophageal cancer	2.97e-06	2.49e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—CYP1B1—esophageal cancer	2.97e-06	2.49e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—TPI1—esophageal cancer	2.96e-06	2.48e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GSTO1—esophageal cancer	2.96e-06	2.48e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—SMAD4—esophageal cancer	2.95e-06	2.48e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CYP2A6—esophageal cancer	2.94e-06	2.46e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—PIK3CA—esophageal cancer	2.93e-06	2.46e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—HIF1A—esophageal cancer	2.93e-06	2.45e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.93e-06	2.45e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—CREBBP—esophageal cancer	2.91e-06	2.44e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—CREBBP—esophageal cancer	2.9e-06	2.43e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—NOTCH1—esophageal cancer	2.9e-06	2.43e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CREBBP—esophageal cancer	2.88e-06	2.42e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NOTCH1—esophageal cancer	2.87e-06	2.41e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KDR—esophageal cancer	2.85e-06	2.39e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—TP53—esophageal cancer	2.84e-06	2.38e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ALDOB—esophageal cancer	2.84e-06	2.38e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NOTCH1—esophageal cancer	2.83e-06	2.37e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—EGFR—esophageal cancer	2.83e-06	2.37e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.8e-06	2.35e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KDR—esophageal cancer	2.8e-06	2.35e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CYP1B1—esophageal cancer	2.79e-06	2.34e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—CYP19A1—esophageal cancer	2.79e-06	2.34e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTGS1—esophageal cancer	2.78e-06	2.33e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ENO1—esophageal cancer	2.78e-06	2.33e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CYP1B1—esophageal cancer	2.77e-06	2.32e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PSME1—esophageal cancer	2.74e-06	2.3e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PSME2—esophageal cancer	2.74e-06	2.3e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GAPDH—esophageal cancer	2.73e-06	2.29e-05	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—PIK3CA—esophageal cancer	2.71e-06	2.27e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CRABP1—esophageal cancer	2.71e-06	2.27e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NOTCH1—esophageal cancer	2.68e-06	2.25e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NOTCH1—esophageal cancer	2.64e-06	2.21e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CYP19A1—esophageal cancer	2.63e-06	2.2e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CREBBP—esophageal cancer	2.63e-06	2.2e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—MYC—esophageal cancer	2.63e-06	2.2e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—MYC—esophageal cancer	2.62e-06	2.2e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CYP19A1—esophageal cancer	2.61e-06	2.18e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—NOS3—esophageal cancer	2.6e-06	2.18e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CREBBP—esophageal cancer	2.6e-06	2.18e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—HIF1A—esophageal cancer	2.6e-06	2.18e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—NOS3—esophageal cancer	2.6e-06	2.18e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—EGFR—esophageal cancer	2.58e-06	2.16e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—NOS3—esophageal cancer	2.58e-06	2.16e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GNG7—esophageal cancer	2.57e-06	2.16e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CREBBP—esophageal cancer	2.57e-06	2.15e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—EGFR—esophageal cancer	2.57e-06	2.15e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—EGFR—esophageal cancer	2.56e-06	2.15e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—EGFR—esophageal cancer	2.56e-06	2.14e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—HMOX1—esophageal cancer	2.54e-06	2.13e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—EGFR—esophageal cancer	2.52e-06	2.12e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KDR—esophageal cancer	2.49e-06	2.09e-05	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—PIK3CA—esophageal cancer	2.47e-06	2.07e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—PIK3CA—esophageal cancer	2.46e-06	2.06e-05	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—PIK3CA—esophageal cancer	2.44e-06	2.05e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CREBBP—esophageal cancer	2.43e-06	2.04e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—HIF1A—esophageal cancer	2.42e-06	2.03e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—ERBB2—esophageal cancer	2.41e-06	2.02e-05	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—PIK3CA—esophageal cancer	2.41e-06	2.02e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ALDH2—esophageal cancer	2.41e-06	2.02e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—HMOX1—esophageal cancer	2.4e-06	2.01e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.4e-06	2.01e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CREBBP—esophageal cancer	2.39e-06	2.01e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—EGFR—esophageal cancer	2.39e-06	2e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PTGS2—esophageal cancer	2.38e-06	2e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—HMOX1—esophageal cancer	2.38e-06	1.99e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PTGS2—esophageal cancer	2.38e-06	1.99e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CYP1B1—esophageal cancer	2.37e-06	1.98e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—CREBBP—esophageal cancer	2.36e-06	1.98e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—NOS3—esophageal cancer	2.35e-06	1.97e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—EGFR—esophageal cancer	2.35e-06	1.97e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NOTCH1—esophageal cancer	2.34e-06	1.96e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.33e-06	1.96e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NOS3—esophageal cancer	2.33e-06	1.95e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.31e-06	1.94e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KDR—esophageal cancer	2.31e-06	1.94e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—ABCB1—esophageal cancer	2.3e-06	1.93e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NOS3—esophageal cancer	2.3e-06	1.93e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GSTT1—esophageal cancer	2.29e-06	1.92e-05	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—PIK3CA—esophageal cancer	2.28e-06	1.91e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—ABCB1—esophageal cancer	2.28e-06	1.91e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CYP2A6—esophageal cancer	2.27e-06	1.9e-05	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—PIK3CA—esophageal cancer	2.25e-06	1.88e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—PIK3CA—esophageal cancer	2.24e-06	1.88e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—PIK3CA—esophageal cancer	2.23e-06	1.87e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CYP19A1—esophageal cancer	2.23e-06	1.87e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—PIK3CA—esophageal cancer	2.22e-06	1.86e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—PIK3CA—esophageal cancer	2.22e-06	1.86e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—ERBB2—esophageal cancer	2.2e-06	1.84e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—PIK3CA—esophageal cancer	2.19e-06	1.84e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—ERBB2—esophageal cancer	2.18e-06	1.83e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NOTCH1—esophageal cancer	2.18e-06	1.83e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NOS3—esophageal cancer	2.18e-06	1.82e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—CREBBP—esophageal cancer	2.17e-06	1.82e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TP53—esophageal cancer	2.16e-06	1.81e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TP53—esophageal cancer	2.15e-06	1.8e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—ERBB2—esophageal cancer	2.15e-06	1.8e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ENO1—esophageal cancer	2.15e-06	1.8e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTGS1—esophageal cancer	2.15e-06	1.8e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NOS3—esophageal cancer	2.14e-06	1.8e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CCND1—esophageal cancer	2.13e-06	1.79e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CREBBP—esophageal cancer	2.12e-06	1.78e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PSME1—esophageal cancer	2.12e-06	1.78e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PSME2—esophageal cancer	2.12e-06	1.78e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—NOS3—esophageal cancer	2.11e-06	1.77e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—EGFR—esophageal cancer	2.09e-06	1.75e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—PIK3CA—esophageal cancer	2.07e-06	1.74e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CDKN1A—esophageal cancer	2.06e-06	1.73e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—CREBBP—esophageal cancer	2.04e-06	1.71e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—PIK3CA—esophageal cancer	2.04e-06	1.71e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—ERBB2—esophageal cancer	2.04e-06	1.71e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—HMOX1—esophageal cancer	2.03e-06	1.7e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—ERBB2—esophageal cancer	2e-06	1.68e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—PIK3CA—esophageal cancer	2e-06	1.67e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.99e-06	1.67e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—EP300—esophageal cancer	1.98e-06	1.66e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—EP300—esophageal cancer	1.98e-06	1.66e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CREBBP—esophageal cancer	1.97e-06	1.65e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—EP300—esophageal cancer	1.96e-06	1.65e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ABCB1—esophageal cancer	1.95e-06	1.63e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CCND1—esophageal cancer	1.94e-06	1.63e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—NOS3—esophageal cancer	1.94e-06	1.63e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—EGFR—esophageal cancer	1.94e-06	1.63e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTGS2—esophageal cancer	1.93e-06	1.62e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CCND1—esophageal cancer	1.92e-06	1.61e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NOS3—esophageal cancer	1.9e-06	1.59e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CCND1—esophageal cancer	1.9e-06	1.59e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CDKN1A—esophageal cancer	1.88e-06	1.58e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CDKN1A—esophageal cancer	1.86e-06	1.56e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.85e-06	1.55e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CDKN1A—esophageal cancer	1.84e-06	1.54e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—NOS3—esophageal cancer	1.83e-06	1.53e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.83e-06	1.53e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—PIK3CA—esophageal cancer	1.81e-06	1.52e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCND1—esophageal cancer	1.8e-06	1.51e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EP300—esophageal cancer	1.79e-06	1.5e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ERBB2—esophageal cancer	1.78e-06	1.49e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTGS2—esophageal cancer	1.78e-06	1.49e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EP300—esophageal cancer	1.77e-06	1.49e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCND1—esophageal cancer	1.77e-06	1.48e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NOS3—esophageal cancer	1.77e-06	1.48e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EP300—esophageal cancer	1.75e-06	1.47e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CDKN1A—esophageal cancer	1.74e-06	1.46e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.73e-06	1.45e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.72e-06	1.44e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CDKN1A—esophageal cancer	1.71e-06	1.44e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MYC—esophageal cancer	1.71e-06	1.43e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—PIK3CA—esophageal cancer	1.68e-06	1.41e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTGS2—esophageal cancer	1.67e-06	1.4e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—EGFR—esophageal cancer	1.67e-06	1.4e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EP300—esophageal cancer	1.66e-06	1.39e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ERBB2—esophageal cancer	1.65e-06	1.39e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—CREBBP—esophageal cancer	1.63e-06	1.37e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EP300—esophageal cancer	1.63e-06	1.37e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—EP300—esophageal cancer	1.61e-06	1.35e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCND1—esophageal cancer	1.57e-06	1.32e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.57e-06	1.31e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MYC—esophageal cancer	1.56e-06	1.31e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MYC—esophageal cancer	1.54e-06	1.29e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CREBBP—esophageal cancer	1.54e-06	1.29e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CREBBP—esophageal cancer	1.52e-06	1.28e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MYC—esophageal cancer	1.52e-06	1.28e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EGFR—esophageal cancer	1.52e-06	1.28e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CDKN1A—esophageal cancer	1.52e-06	1.27e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EGFR—esophageal cancer	1.51e-06	1.27e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.5e-06	1.26e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EGFR—esophageal cancer	1.49e-06	1.25e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—EP300—esophageal cancer	1.48e-06	1.24e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.47e-06	1.24e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PIK3CA—esophageal cancer	1.46e-06	1.23e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—NOS3—esophageal cancer	1.46e-06	1.23e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PIK3CA—esophageal cancer	1.46e-06	1.23e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCND1—esophageal cancer	1.46e-06	1.22e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PIK3CA—esophageal cancer	1.45e-06	1.22e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EP300—esophageal cancer	1.45e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MYC—esophageal cancer	1.44e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MYC—esophageal cancer	1.42e-06	1.19e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CDKN1A—esophageal cancer	1.41e-06	1.18e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EGFR—esophageal cancer	1.41e-06	1.18e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—esophageal cancer	1.4e-06	1.18e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—EP300—esophageal cancer	1.39e-06	1.17e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EGFR—esophageal cancer	1.39e-06	1.16e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—NOS3—esophageal cancer	1.38e-06	1.15e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—NOS3—esophageal cancer	1.37e-06	1.14e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EP300—esophageal cancer	1.34e-06	1.13e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTGS2—esophageal cancer	1.34e-06	1.12e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PIK3CA—esophageal cancer	1.32e-06	1.11e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PIK3CA—esophageal cancer	1.31e-06	1.1e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CREBBP—esophageal cancer	1.3e-06	1.09e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PIK3CA—esophageal cancer	1.29e-06	1.08e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—esophageal cancer	1.28e-06	1.07e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—esophageal cancer	1.27e-06	1.06e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MYC—esophageal cancer	1.26e-06	1.06e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTGS2—esophageal cancer	1.26e-06	1.06e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—esophageal cancer	1.25e-06	1.05e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTGS2—esophageal cancer	1.25e-06	1.05e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EGFR—esophageal cancer	1.23e-06	1.03e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PIK3CA—esophageal cancer	1.22e-06	1.03e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PIK3CA—esophageal cancer	1.2e-06	1.01e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PIK3CA—esophageal cancer	1.19e-06	9.97e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—esophageal cancer	1.18e-06	9.93e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MYC—esophageal cancer	1.17e-06	9.82e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—NOS3—esophageal cancer	1.17e-06	9.78e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—esophageal cancer	1.17e-06	9.77e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EGFR—esophageal cancer	1.15e-06	9.61e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—EP300—esophageal cancer	1.11e-06	9.32e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PIK3CA—esophageal cancer	1.09e-06	9.16e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PIK3CA—esophageal cancer	1.07e-06	8.97e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTGS2—esophageal cancer	1.07e-06	8.95e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—EP300—esophageal cancer	1.05e-06	8.78e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—EP300—esophageal cancer	1.04e-06	8.71e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—esophageal cancer	1.04e-06	8.68e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CA—esophageal cancer	1.03e-06	8.63e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CREBBP—esophageal cancer	1.01e-06	8.43e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CA—esophageal cancer	9.94e-07	8.34e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—esophageal cancer	9.62e-07	8.07e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—NOS3—esophageal cancer	9e-07	7.55e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—EP300—esophageal cancer	8.87e-07	7.44e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTGS2—esophageal cancer	8.24e-07	6.9e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CA—esophageal cancer	8.22e-07	6.89e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CA—esophageal cancer	7.75e-07	6.5e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CA—esophageal cancer	7.68e-07	6.44e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—EP300—esophageal cancer	6.85e-07	5.74e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CA—esophageal cancer	6.57e-07	5.5e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CA—esophageal cancer	5.07e-07	4.25e-06	CbGpPWpGaD
